U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Serum-Free Medium for the Isolation and Expansion of Canine Adipose-Derived Mesenchymal Stem/Stromal Cells
  1. Licensing and Collaboration Opportunities

Serum-Free Medium for the Isolation and Expansion of Canine Adipose-Derived Mesenchymal Stem/Stromal Cells

Download the Abstract (PDF -100KB)

Technology Summary

Mesenchymal Stem/Stromal Cells (MSCs) are a potentially effective therapy for treating a variety of conditions in veterinary medicine. MSCs are isolated and expanded in vitro in a medium that is supplemented with fetal bovine serum (FBS). However, the use of FBS as a medium component during manufacturing may pose several problems. FBS can be a source of unwanted pathogens, the serum can introduce carry-over components that may elicit an immune response, and lot-to-lot variations in FBS quality may introduce inconsistencies between batches of MSCs.

This invention is a novel FBS-free medium that supports both the isolation and expansion of MSCs from canine adipose tissue while removing the unwanted pathogens, immune response and lot-to-lot variations.

Potential Commercial Applications Competitive Advantages
  • An isolation and expansion technique for manufacturing large quantities of MSCs in an FBS-free medium
  • The FBS-free medium removes the potential for adventitious pathogens, unwanted immune response and lot variations in MSCs during manufacture.
  • The MSCs cultivated in this novel medium exhibit a more uniform size and a shorter population doubling time as compared to the FBS medium.

Development Stage: Research Material

Inventors: Lax Devireddy, Michael Myers, Rudell Screven


  • Devireddy, LR., et. al. A serum-free medium formulation efficiently supports isolation and propagation of canine adipose-derived mesenchymal stem/stromal cells. PLoS One. 2019 Feb 27;14(2) PMID: 30811421

Product Area:  research material, supplement, media, serum

FDA Reference No: E-2017-010

Licensing Contact:
Ken Millburne, J.D.
FDA Technology Transfer Program
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-2245

Back to Top